Related Experiment Video
Updated: Oct 9, 2025
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.3K
Pulmonary Hypertension and COVID-19
Laura Castiglione1, Michal Droppa1
1Department of Cardiology and Angiology, University Hospital Tübingen, Tübingen, Germany.
Hamostaseologie
|December 21, 2021
Summary
COVID-19 can cause pulmonary hypertension (PH), a serious condition affecting lung blood flow. Early research suggests inhaled vasodilators may help treat this complication, but more clinical trials are needed.
Area of Science:
- Cardiology
- Pulmonology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19) is a global pandemic with potential cardiovascular and pulmonary complications.
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce pulmonary hypertension (PH) through endothelial dysfunction and thrombotic microangiopathy.
- Approximately 12-13% of hospitalized COVID-19 patients exhibit echocardiographic signs of PH, indicating a significant association with disease severity and adverse outcomes.
Purpose of the Study:
- To explore the potential therapeutic benefits of inhaled vasodilators in managing COVID-19-associated pulmonary hypertension.
- To investigate the role of pulmonary hemodynamics in the pathophysiology of COVID-19.
- To summarize current evidence on PH in COVID-19 patients and potential treatment strategies.
Main Methods:
- Review of clinical research and available studies on COVID-19 and pulmonary hypertension.
- Analysis of echocardiographic data in hospitalized COVID-19 patients.
- Evaluation of the effects of inhaled vasodilators, such as nitric oxide and prostacyclin.
Main Results:
- Inhaled vasodilators like nitric oxide and prostacyclin have shown promising results in improving oxygenation and reducing pulmonary arterial pressure.
- Treatment with inhaled vasodilators may help prevent right ventricular failure in COVID-19 patients with PH.
- Existing studies indicate a link between PH and increased COVID-19 severity and poorer prognosis.
Conclusions:
- Pulmonary hypertension is a significant complication of COVID-19, linked to worse patient outcomes.
- Inhaled vasodilators represent a potential therapeutic avenue for COVID-19-related PH, warranting further investigation.
- Randomized controlled trials are necessary to confirm the efficacy and safety of inhaled vasodilators in this patient population.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
318
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
318
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.0K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
341
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
341
01:29Pulmonary Embolism I: Introduction
173
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
173
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
277
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
277
01:20COPD: Pathogenesis and Clinical Features
678
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
678